Vanessa Bach
Research Subjects
Vanessa Bach has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Anuska Llano
IrsiCaixa AIDS Research Institute-HIVACAT, Hospital Universitari Germans Trias i Pujol, 08916 Barcelona, Spain
1 shared publication - Beatriz Mothe
IrsiCaixa, Hospital Universitari Germans Trias I Pujol
1 shared publication - Bette Korber
Los Alamos National Laboratory, Los Alamos, NM 87545, USA
1 shared publication - Bonaventura Clotet
IrsiCaixa, Badalona, Spain
1 shared publication - Bruce D. Walker
Ragon Institute of MGH, MIT and Harvard
1 shared publication - Chanson J. Brumme
Affiliations British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, Department of Medicine, University of British Columbia, Vancouver, Canada
1 shared publication
Latest Publications
- Open Access
- 7 December 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 208
Definition of the viral targets of protective HIV-1-specific T cell responses
Background: The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell function and specificity. Methods: Here, 950 untreated HIV-1 clade B or -C infected individuals were tested for responses to sets of 410 overlapping peptides (OLP) spanning the entire HIV-1 proteome. For each OLP, a "protective ratio" (PR) was calculated as the ratio of median viral loads (VL) between OLP non-responders and responders. Results: For both clades, there was a negative relationship between the PR and the entropy of the OLP sequence. There was also a significant additive effect of multiple responses to beneficial OLP. Responses to beneficial OLP were of significantly higher functional avidity than responses to non-beneficial OLP. They also had superior in-vitro antiviral activities and, importantly, were at least as predictive of individuals' viral loads than their HLA class I genotypes. Conclusions: The data thus identify immunogen sequence candidates for HIV and provide an approach for T cell immunogen design applicable to other viral infections.
- 7 December 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 208
Open AccessDefinition of the viral targets of protective HIV-1-specific T cell responses
Background: The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell function and specificity. Methods: Here, 950 untreated HIV-1 clade B or -C infected individuals were tested for responses to sets of 410 overlapping peptides (OLP) spanning the entire HIV-1 proteome. For each OLP, a "protective ratio" (PR) was calculated as the ratio of median viral loads (VL) between OLP non-responders and responders. Results: For both clades, there was a negative relationship between the PR and the entropy of the OLP sequence. There was also a significant additive effect of multiple responses to beneficial OLP. Responses to beneficial OLP were of significantly higher functional avidity than responses to non-beneficial OLP. They also had superior in-vitro antiviral activities and, importantly, were at least as predictive of individuals' viral loads than their HLA class I genotypes. Conclusions: The data thus identify immunogen sequence candidates for HIV and provide an approach for T cell immunogen design applicable to other viral infections.